Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.07.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Robert S Rosenson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA (Dr Rosenson). Electroni…. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Pancreatitis, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc.
Abstract (Originalsprache)
BACKGROUND: Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis (AP). OBJECTIVE: To evaluate the efficacy of a 20 mg/kg dose of intravenous evinacumab vs placebo on sHTG-associated episodes of AP. METHODS: This phase 2b study (NCT04863014) enrolled adults with sHTG and a history of hypertriglyceridemia-associated AP. Eligible patients were randomly assigned to intravenous evinacumab 20 mg/kg or placebo every 4 weeks over a 52-week double-blind treatment period. RESULTS: Forty patients were screened; 21 patients received either evinacumab (n = 11) or placebo (n = 10). Twelve (57.1%) patients completed the study. The proportion of patients with ≥1 positively adjudicated AP episode during the 52-week treatment period (primary endpoint) was 27.3% (n = 3) with evinacumab vs 10.0% (n = 1) with placebo. All positively adjudicated AP episodes occurred ≥58 days after the last evinacumab dose, when evinacumab concentrations were mostly near or below the limit of quantitation. The median percentage change in triglycerides from baseline to week 4 was -55.3% with evinacumab vs +1.5% with placebo. By week 16, evinacumab reduced triglycerides by 95.7%; the effect was maintained in 1 patient who received treatment through week 52. Incidence of treatment-emergent adverse events was lower with evinacumab (63.6%) than with placebo (100.0%). CONCLUSION: Although the sample size was too small to determine whether evinacumab can prevent AP, the data suggest evinacumab may be efficacious in lowering triglyceride concentrations in patients with sHTG and a history of sHTG-associated AP. Tolerability and safety of evinacumab was consistent with previous studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA (Dr Rosenson). Electronic address: robert.rosenson@mssm.edu.
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA (Drs George, Sanchez, Zhao, Ponda, Waldron, and Pordy).
Förderung
- Regeneron Pharmaceuticals Inc
Zitieren
APA
Rosenson, R. S., George, R. T., Sanchez, R. J., Zhao, X. Q., Ponda, M. P., Waldron, A., & Pordy, R. (2025). Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.07.005
Vancouver
Rosenson RS, George RT, Sanchez RJ, Zhao XQ, Ponda MP, Waldron A, et al. Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.07.005
BibTeX
@article{Rosenson2025,
author = {Rosenson, Robert S and George, Richard T and Sanchez, Robert J and Zhao, Xue-Qiao and Ponda, Manish P and Waldron, Alpana and Pordy, Robert},
title = {Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.07.005}
}
EUVIMED